German Federal Joint Committee (G-BA)
24
Jun 2021
On June 7, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has reported that 123 project ideas were received for Innovation Funding of the new forms of care within the new two-stage application process framework.
Read more
26
May 2021
On May 6, 2021, the Federal Joint Committee (G-BA) announced the start of consultations about the design of three co-funded studies for cardiovascular methods in accordance with §137e SGB V.
Read more
19
May 2021
The Innovation Committee at the Federal Joint Committee (G-BA) has launched the decisions database on its website.
Read more
25
Mar 2021
On March 17, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities. Applicants are invited to submit ideas for projects that fall within one of these funding priorities. The deadline for submitting ideas is June 1, 2021.
Read more
11
Feb 2021
On January 28, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) published the first overview of the 28 innovative projects on new forms of medical care that will be funded. The projects concerning the technologies belonging to the cardiovascular, eHealth, orthopedic, neurology, nephrology, and other technology groups received funding.
Read more
11
Jan 2021
In late December 2020, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding from the G-BA Innovation Fund of twenty-eight innovative projects on new forms of medical care.
Read more
26
Nov 2020
On November 9, 2020, in accordance with §137h Paragraph 6 SGB V, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency within the framework of the early benefit assessment.
Read more
28
Oct 2020
In mid-October 2020, the Federal Joint Committee (G-BA) has decided that three more biomarker-based tests in breast cancer will be covered by the statutory health insurance. Since January 2020, the "Oncotype DX Breast Recurrence Score" test is already reimbursed in Germany with a tariff of €3,296.50.
Read more
30
Jul 2020
In late June 2020, the Innovation Committee at the Federal Joint Committee (G-BA) published funding priorities on its website. For the first time, the decision on the funding priorities was preceded by a consultation process. Healthcare stakeholders who are not members of the Innovation Committee were asked to come up with suggestions for funding topics and criteria.
Read more
14
May 2020
The corresponding decision by the (the Federal Joint Committee) of January 16, 2020, was published in the Federal Gazette and came into force on April 9, 2020.
Read more
23
Apr 2020
The revised EBM (German Uniform Evaluation Standard) comes into force on April 1, 2020. Among others, the amendments made concern the billing of the services within the framework of early detection of cervical cancer. Also, the new fee order item (GOP) for the human papillomaviruses (HPV) genotyping service was added.
Read more
16
Apr 2020
Patients with a newly diagnosed glioblastoma will have an opportunity to benefit from the therapy with tumor-treating fields (TTF) at the expense of statutory health insurance. The Federal Joint Committee (G-BA) decided on March 20, 2020, the details concerning the indications and the quality assurance measures that will apply when prescribing this outpatient treatment method.
Read more